A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Jeremy B FooteTyler E MattoxAdam B KeetonXi ChenForrest SmithKristy L BerryThomas HolmesJunwei WangChung-Hui HuangAntonio B WardAmit K MitraVeronica Ramirez-AlcantaraCherlene HardyKarrianne G FletenKjersti FlatmarkKarina J YoonSujith SarveshGanji Purnachandra NagarajuYulia MaxuitenkoJacob ValiyaveettilJulienne L CarstensDonald J BuchsbaumJennifer YangGang ZhouElmar NurmemmedovIvan BabicVadim GaponenkoHazem AbdelkarimMichael R BoydGregory S GormanUpender ManneSejong BaeBassel F El-RayesGary A PiazzaPublished in: bioRxiv : the preprint server for biology (2024)
-in-class pan-RAS inhibitor with ultra-high potency and unique selectivity for cancer cells with mutant or activated RAS capable of circumventing resistance and activating antitumor immunity. Further development of ADT-007 analogs or prodrugs with oral bioavailability as a generalizable monotherapy or combined with immunotherapy is warranted.